ArticleJournal of traditional and complementary medicine2025
Integrating pharmacokinetics and network pharmacology to decipher the efficacy of Fufang Qinlan oral liquid on post infectious cough.
Article in Journal of traditional and complementary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Fufang Qinlan oral liquid (QLOL) is a traditional Chinese medicine formula used to treat fevers, sore throats and cough. This study was to evaluate QLOL's therapeutic effects on post infectious cough (PIC) and to investigate Q-markers and action mechanisms by integrating pharmacokinetics and network pharmacology. Materials and methods: PIC rats were measured for cough frequency, organ index, pathological section of lung and inflammatory factors to evaluate the effects of QLOL. Pharmacokinetic analyses were performed using HPLC-QQQ-MS/MS to explore the possible Q-markers of QLOL and the changes of them Results: The symptoms of cough and lung injury were significantly alleviated and IL-6 and IL-1β were significantly decreased after treatment of QLOL. 6 compounds were considered as possible Q-makers and their pharmacokinetic parameters were analyzed. The compound-target network was constructed to identify 53 important targets. Among them, HSPA8, HSP90AA1, HSP90AB1, YWHAZ, EGFR, ESR1 and EP300 were selected as the core targets because of high degree value and direct connection with inflammation or microbial infection. All 6 compounds had potently binding activity to core targets in molecular docking. The QPCR results showed the up-regulation of core targets expression in QLOL group compared with PIC rats, which validated the effects of QLOL and the accuracy of Q-markers selection. Conclusion: QLOL alleviated PIC symptoms through various targets and mechanisms. The potential Q-markers were baicalein, baicalin, oroxylin A-7- Taxonomy classification by evise: the experimental approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.